Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.jhealeco.2023.102754
DC Field | Value | |
---|---|---|
dc.title | The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B | |
dc.contributor.author | Han, Dan | |
dc.date.accessioned | 2023-06-27T00:47:21Z | |
dc.date.available | 2023-06-27T00:47:21Z | |
dc.date.issued | 2023-05 | |
dc.identifier.citation | Han, Dan (2023-05). The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B. JOURNAL OF HEALTH ECONOMICS 89. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhealeco.2023.102754 | |
dc.identifier.issn | 0167-6296 | |
dc.identifier.issn | 1879-1646 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/242537 | |
dc.description.abstract | I study the impact of expanding the 340B Drug Pricing Program to include Critical Access Hospitals (CAH) on Medicare Part B drug utilization and spending. The 340B program entitles certain hospitals and clinics to discounts on most outpatient drugs. In 2010, the Affordable Care Act expanded 340B eligibility to CAHs — small rural hospitals that receive cost-based reimbursement from Medicare. Exploiting variation in the predicted exposure to the 340B expansion in a difference-in-differences method, I find that the 340B expansion reduced Part B drug spending but did not affect Part B drug utilization. This finding contrasts with existing evidence about 340B's impact on hospitals but is consistent with the prediction that cost-based reimbursement dampens the incentives created by the 340B discounts. I also find suggestive evidence that CAHs passed the cost savings from 340B on to patients. These results add new perspectives to the ongoing debate over 340B. | |
dc.language.iso | en | |
dc.publisher | ELSEVIER | |
dc.source | Elements | |
dc.subject | Social Sciences | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Economics | |
dc.subject | Health Care Sciences & Services | |
dc.subject | Health Policy & Services | |
dc.subject | Business & Economics | |
dc.subject | 340B | |
dc.subject | Drug Pricing | |
dc.subject | Critical Access Hospitals | |
dc.subject | Cost-based reimbursement | |
dc.subject | Medicare | |
dc.subject | CONSEQUENCES | |
dc.subject | CARE | |
dc.type | Article | |
dc.date.updated | 2023-06-26T13:36:27Z | |
dc.contributor.department | DEAN'S OFFICE (LKY SCH OF PUBLIC POLICY) | |
dc.description.doi | 10.1016/j.jhealeco.2023.102754 | |
dc.description.sourcetitle | JOURNAL OF HEALTH ECONOMICS | |
dc.description.volume | 89 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
1-s2.0-S0167629623000310-main.pdf | Published version | 4.95 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.